A single-center prospective study of Tix-Cil in preventing SARS-CoV-2 infection in RTX-treated ARD patients
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Cilgavimab/tixagevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 23 Jul 2024 New trial record
- 15 Jun 2024 Results (Between October and December 2022) assessing the efficacy and safety of Tix-Cil in preventing SARS-CoV-2 infection in RTX-treated ARD patients, presented at the 25th Annual Congress of the European League Against Rheumatism.